Investigators said analysis of multiple tissues from the same patients suggests tumor evolution in high-grade serous ovarian cancer (HGSC) was not through somatic mutations.
A new report offers a deeper understanding of germline and somatic variation in patients with high-grade serous ovarian cancer (HGSC).
The report is based on an analysis of 71 patients with HGSC. It was published in Journal of Ovarian Research.
Patients with HGSC often receive their diagnosis at a late stage, noted the study authors, and typically undergo both surgical cytoreduction and chemotherapy, they said, although targeted therapies are becoming more and more common. Still, they noted that the 5-year survival rate is only 20% to 30%.
“These dismal statistics underscore the need for earlier detection and new treatments following diagnosis,” they said.
HGSC is characterized by complex genetic alterations, the authors said. The goal of the new study was to better understand those alterations, as well as their associations with relapse and survival rates.
The authors recruited 71 participants with stage III or IV HGSC who were treated at City of Hope and who underwent their first debulking surgery between 2002 and 2014. In most cases, tumor tissue was sequenced from the first debulking surgery, including 63 from the primary site and 6 from metastatic sites. In the other 2 patients, tumor tissue was only available from the second debulking. Fifteen patients had tumor tissue available from the first and second debulking surgeries, and in 3 cases, tumor tissue was available from 3 surgeries. Twelve patients had samples taken from multiple tumor sites during the same primary surgery, the authors said.
The investigators performed targeted germline and tumor sequencing on the patients and a comprehensive analysis of 557 genes involved in DNA damage response and the PI3K/AKT/mTOR pathways. They also performed OncoScan assays on tumor DNA from 61 patients to examine somatic copy number alterations (SCNAs).
“Approximately one-third of tumors had loss-of-function (LOF) germline (18/71, 25.4%) or somatic (7/71, 9.9%) variants in the DNA homologous recombination repair pathway genes BRCA1, BRCA2, CHEK2, MRE11A, BLM, and PALB2,” the authors said.
LOF germline variants were also found in other Fanconi anemia genes and in MAPK and PI3K/AKT/mTOR pathway genes, they said. Almost all (65/71) tumors harbored somatic TP53 variants, they said. The OncoScan analysis showed focal homozygous deletions in BRCA1, BRCA2, MAP2K4, PTEN, RB1, SLX4, STK11, CREBBP, and NF1, they said.
“In total, 38% (27/71) of HGSC patients harbored pathogenic variants in DNA homologous recombination repair genes,” they found.
The authors noted they found that somatic mutations were generally maintained among patients with multiple tissues, “suggesting that tumor evolution was not true somatic mutations.” They also said they found a significant association between LOF variants in homologous recombination repair pathway genes and high-amplitude SCNAs.
“Using GISTIC analysis, we identified NOTCH3, ZNF536, and PIK3R2 in these regions that were significantly associated with an increase in cancer recurrence and a reduction in overall survival,” they said.
The investigators said these findings add to the scientific understanding of HGSC and provide insights into genetic alterations and their impact on patient outcomes.
“Our findings suggest that targeted treatments based on both variant and SCNA profile potentially could improve relapse-free and overall survival,” they concluded.
Reference
Adamson AW, Ding YC, Steele L, et al. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer. J Ovarian Res. Published online July 17, 2023. doi:10.1186/s13048-023-01234-x
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More